Biomarkers in Colorectal Cancer: A Longitudinal Study Using Biobanks and Blood Samples
Official title: Prospective Cohort Study to Investigate Clinical Factors and Molecular Biomarkers Associated With Treatment Response and Disease Outcomes in Patients With Colorectal Cancer in Vorarlberg, Austria
Run by Vorarlberg Institute for Vascular Investigation and Treatment · NCT07913802 · Data updated 2026-11-12
This study tests whether clinical and molecular biomarkers from tumor tissue and blood can predict treatment response, recurrence, and survival in adults with colorectal cancer undergoing surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Vorarlberg Institute for Vascular Investigation and Treatment Academic / other |
| Locations | 4 sites (Bregenz, Vorarlberg and 3 other locations) |
| Status | Recruiting |
| Started | October 23, 2023 |
| Main results expected | October 2028 |
| Study ends | October 2033 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT07913802 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older with histologically confirmed colorectal cancer planned for surgical resection.
✕Probably not a fit
Patients who do not harbor actionable biomarkers or whose disease biology does not correlate with the studied biomarkers may not experience direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter observational study enrolling about 200 adults with colorectal cancer who will have surgical resection. Researchers will collect tumor tissue, adjacent non-malignant tissue, and blood samples, and link these with detailed clinical data over up to five years to explore associations with outcomes. Analyses will include tumor genetics, circulating tumor DNA, gene expression, and other biomarkers to understand prognosis and potential personalized approaches. All treatment decisions will follow standard care and are not influenced by study participation. The project aims to establish a biobank linked to clinical information to support future biomarker-driven research.
Why it matters
Potential benefit: If successful, patients could benefit from improved risk stratification and better guidance for surveillance or tailored therapies based on biomarker profiles.
How similar studies have gone: Biomarker and ctDNA studies in colorectal cancer have shown promise in prognosis and monitoring, but this study seeks to expand longitudinal biobanking across multiple centers.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years. * Histologically confirmed colorectal carcinoma. * Planned surgical resection of the primary colorectal tumor. * Written informed consent to participate in the study. Exclusion Criteria: * Age \<18 years. * Pregnancy. * Individuals held in custody by order of a court or public authority. * Known current alcohol and/or illicit drug abuse that, in the investigator's judgment, may compromise participant safety and/or compliance. * Inability to understand and sign the informed consent form.
Where it's running
-
Landeskrankenhaus Bregenz
Bregenz, Vorarlberg, Austria Recruiting -
Landeskrankenhaus Feldkirch
Feldkirch, Vorarlberg, Austria Recruiting -
Landeskrankenhaus Hohenems
Hohenems, Vorarlberg, Austria Active not recruiting -
Landeskrankenhaus Rankweil
Rankweil, Vorarlberg, Austria Active not recruiting
Study contacts
- Principal investigator: Thomas Winder, MD, PhD — Landeskrankenhaus Feldkirch
- Study coordinator: Thomas Winder, MD, PhD
- Email: Thomas.Winder@vlkh.at
- Phone: +43 5522 3032694
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer
A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.
-
Multimodal Survival Predictor for Colorectal Liver Metastases After Surgery
Researchers are testing a tool that combines MRI-derived tumor features with clinical data to predict survival after surgery for colorectal liver metastases.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
AI-powered stool image analysis to see if it matches FIT results in colorectal cancer screening
We’re testing whether AI-derived features from stool images can align with FIT results in adults being screened or evaluated for colorectal neoplasia.
-
A web-based tool to help predict submucosal invasive cancer in large non-pedunculated colorectal polyps
A web-based decision aid is being tested to see if it can help endoscopists predict cancer invasion in large non-pedunculated colorectal polyps during live colonoscopies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.